NCT07050732View on ClinicalTrials.gov

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2028

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

Arexvy (2 doses total)

Arexvy at enrollment, Arexvy at Day 365

BIOLOGICAL

Arexvy (3 doses total)

Arexvy at enrollment, Day 60, and Day 365

BIOLOGICAL

Arexvy (1 dose total)

Arexvy at enrollment

OTHER

Placebo

Placebo vaccine at day 60

Trial Locations (1)

21205

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Johns Hopkins University

OTHER